# Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

> **NCT05397470** · PHASE3 · TERMINATED · sponsor: **Fulcrum Therapeutics** · enrollment: 260 (actual)

## Conditions studied

- Facioscapulohumeral Muscular Dystrophy (FSHD)

## Interventions

- **DRUG:** Losmapimod
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT05397470
- **Lead sponsor:** Fulcrum Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-16
- **Primary completion:** 2024-11-19
- **Final completion:** 2024-11-19
- **Target enrollment:** 260 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05397470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05397470, "Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05397470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*